These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2877981)

  • 1. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.
    Kimura S; Aoki N
    J Biol Chem; 1986 Nov; 261(33):15591-5. PubMed ID: 2877981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor.
    Tamaki T; Aoki N
    J Biol Chem; 1982 Dec; 257(24):14767-72. PubMed ID: 6129243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.
    Ichinose A; Tamaki T; Aoki N
    FEBS Lett; 1983 Mar; 153(2):369-71. PubMed ID: 6617867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
    Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
    J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-Chain cross-linking in fibrin(ogen) Marburg.
    Sobel JH; Trakht I; Wu HQ; Rudchenko S; Egbring R
    Blood; 1995 Aug; 86(3):989-1000. PubMed ID: 7620190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the alpha chain lysine donor sites involved in factor XIIIa fibrin cross-linking.
    Sobel JH; Gawinowicz MA
    J Biol Chem; 1996 Aug; 271(32):19288-97. PubMed ID: 8702612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible cross-linking of alpha 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor.
    Ichinose A; Aoki N
    Biochim Biophys Acta; 1982 Sep; 706(2):158-64. PubMed ID: 6127110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor.
    Kimura S; Tamaki T; Aoki N
    Blood; 1985 Jul; 66(1):157-60. PubMed ID: 3159442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking.
    Achyuthan KE; Dobson JV; Greenberg CS
    Biochim Biophys Acta; 1986 Aug; 872(3):261-8. PubMed ID: 2873839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites.
    Cottrell BA; Strong DD; Watt KW; Doolittle RF
    Biochemistry; 1979 Nov; 18(24):5405-10. PubMed ID: 518845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase.
    Lee KN; Lee CS; Tae WC; Jackson KW; Christiansen VJ; McKee PA
    J Biol Chem; 2000 Dec; 275(48):37382-9. PubMed ID: 10958788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor.
    Tamaki T; Aoki N
    Biochim Biophys Acta; 1981 Oct; 661(2):280-6. PubMed ID: 7295739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody directed to a fibrinogen A alpha #529-539 epitope inhibits alpha-chain crosslinking by transglutaminases.
    Mitkevich OV; Sobel JH; Shainoff JR; Vlasik TN; Kalantarov GF; Trakht IN; Streltsova ZA; Samokhin GP
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):85-92. PubMed ID: 8845468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfation of a tyrosine residue in the plasmin-binding domain of alpha 2-antiplasmin.
    Hortin G; Fok KF; Toren PC; Strauss AW
    J Biol Chem; 1987 Mar; 262(7):3082-5. PubMed ID: 2434496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and characterization of pro alpha 2-plasmin inhibitor.
    Sumi Y; Ichikawa Y; Nakamura Y; Miura O; Aoki N
    J Biochem; 1989 Oct; 106(4):703-7. PubMed ID: 2606916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2).
    Ritchie H; Lawrie LC; Mosesson MW; Booth NA
    Ann N Y Acad Sci; 2001; 936():215-8. PubMed ID: 11460477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and partial structural characterization of an equine fibrinogen CNBr fragment that exhibits immunologic cross-reactivity with an A alpha-chain cross-linking region of human fibrinogen.
    Sobel JH; Thibodeau CA; Kolks MA; Canfield RE
    Biochemistry; 1990 Sep; 29(38):8907-16. PubMed ID: 2271566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why alpha-antiplasmin must be converted to a derivative form for optimal function.
    Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
    J Thromb Haemost; 2007 Oct; 5(10):2095-104. PubMed ID: 17883704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural features of glutamine substrates for human plasma factor XIIIa (activated blood coagulation factor XIII).
    Gorman JJ; Folk JE
    J Biol Chem; 1980 Jan; 255(2):419-27. PubMed ID: 6101325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.